verified SJR 0,813 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Wiley-Blackwell Publishing L...

workspace_premium Q2 — Infectious Diseases lock_open Open Access Unclaimed

Journal of Viral Hepatitis

Journal of Viral Hepatitis is a journal indexed in SJR in Infectious Diseases and Virology with an H index of 112. It has a price of 3350 €. It has an SJR impact factor of 0,813 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,813.

Journal of Viral Hepatitis focuses its scope in these topics and keywords: hepatitis, chronic, virus, infection, patients, treatment, men, response, therapy, sex, ...

ISSN: 1352-0504

Editorial: Wiley-Blackwell Publishing Ltd

Category: Infectious Diseases

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

0,813 Q2

H-index 112

Tasa de Aceptación pie_chart

24% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

3.350 € Open Access

Ruta Non-OA 0 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

0,813

H-index

112

Docs (year)

136

Docs 3y

452

Total refs

4816

Cites 3y

1084

Citable 3y

412

Cites/Doc 2y

2.41

Ref/Doc

35.41

Immediate OA

3350 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Detection of antibodies to hepatitis C virus in seronegative patients using an immune complex dissociation assay

Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C

Expression and characterization of the hepatitis G virus helicase

Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland

Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha2a for chronic hepatitis C with cirrhosis

Editorial

Does twice-weekly administration of peginterferon alfa-2b really improve viral kinetics in patients with chronic hepatitis C genotype 1?

Do undefined sources of hepatitis C transmission exist? The Greek study in General Practice

Do Taq-generated RT-PCR products from RNA viruses accurately reflect viral genetic heterogeneity?

DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response*

SHOW MORE ARTICLES

Detection of hepatitis G virus RNA in patients with acute non-A-E hepatitis

A model to predict long-term sustained response to interferon therapy in chronic hepatitis C

Current prevalence of hepatitis A, B and C in a well-defined area in rural Crete, Greece

Consensus interferon: a novel interferon for the treatment of hepatitis C

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C

Comparison of high initial and fixed-dose regimens of interferon-a2a in chronic hepatitis C: a randomized controlled trial

Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy

Cellular immune response to the hepatitis C virus

An outbreak of enterically transmitted non-A, non-E viral hepatitis

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C

A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B

A prospective study of transfusion-transmitted virus transmission by blood transfusion

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.